OPDP accuses Acorda of improperly marketing MS drug

08/12/2013 | PharmaLive.com

The FDA's Office of Prescription Drug Promotion issued a warning letter to Acorda Therapeutics, accusing it of omitting information on risks, adverse events and contraindications in a newspaper ad for the company's Ampyra multiple sclerosis drug. Acorda was warned last year that a video for the same drug overstated efficacy and minimized risk information.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Claims Director
Springfield, OR
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA